Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

IRESSA Receives Marketing Authorization for the Treatment of Non-Small Cell Lung Cancer in Europe

Published: Tuesday, July 07, 2009
Last Updated: Tuesday, July 07, 2009
Bookmark and Share
European Commission grants marketing authorization for the oral anti-cancer drug.

AstraZeneca announced has that the European Commission has granted marketing authorization for the oral anti-cancer drug, IRESSA for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR-TK across all lines of therapy.

The authorization is based on a submission package including two pivotal Phase III studies comparing IRESSA with chemotherapy, IPASS and INTEREST.

IRESSA acts by inhibiting the tyrosine kinase enzyme in the EGFR, thus blocking the transmission of signals involved in the growth and spread of tumors. A mutation in the EGFR is a characteristic occurring in 10-15% of lung cancers in non-Asians, and studies have shown that these types of tumors are particularly sensitive to IRESSA.

Anders Ekblom, Executive Vice President for Development at AstraZeneca, said: "IRESSA is the first truly targeted treatment for lung cancer, and the EU marketing authorization represents an important step forward in the treatment of this devastating disease. For the first time, patients with EGFR mutation positive tumors will have a more effective and better tolerated alternative to chemotherapy as a first-line treatment.”

AstraZeneca will work closely with clinicians and pathology groups on a country-by-country basis to facilitate appropriate access to EGFR mutation diagnostic testing.

AstraZeneca has agreed to conduct a Follow-up Measure Study to generate further data in a Caucasian NSCLC patient population and is currently in discussion with the EMEA to finalize the study design and endpoints.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More Than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Monday, April 25, 2016
Astrazeneca Supports Crowd Sourcing Challenge to Find Cancer Therapies
AstraZeneca is making available preclinical data from over 50 of its medicines as part of the DREAM Challenge, an open innovation competition, to find the most synergistic drug combinations with the potential to treat cancer.
Wednesday, September 23, 2015
Astrazeneca Purchases Us Biologics Manufacturing Facility
AstraZeneca has added to its biologics manufacturing capability in the US with the purchase of a high-tech biologics bulk manufacturing facility from Amgen Inc.
Monday, September 14, 2015
AstraZeneca, Univ. of Manchester Partner
AstraZeneca and The University of Manchester have announced a collaboration harnessing clinical bioinformatics to deliver personalised healthcare for cancer patients.
Wednesday, September 09, 2015
AstraZeneca and Peregrine Pharmaceuticals to Collaborate
Collaboration on immuno-oncology combination clinical trial.
Friday, August 28, 2015
Medimmune Enters into Collaboration and License Agreement with Inovio
Agreement includes clinical-stage INO-3112 HPV cancer vaccine and preclinical collaboration to develop additional cancer vaccine candidates.
Thursday, August 20, 2015
Heptares, AstraZeneca Collaborate
The companies are set to enter into an agreement to develop novel immuno-oncology treatments for a range of cancers.
Monday, August 10, 2015
AstraZeneca, Isis Pharmaceuticals Collaborate
AstraZeneca and Isis Pharmaceuticals, Inc. have announced a strategic collaboration to discover and develop antisense therapies for cardiovascular, metabolic and renal diseases.
Tuesday, August 04, 2015
AstraZeneca, Lilly to Study Immuno-Oncology Combination
This collaboration sets out to assess the efficacy of a combinatorial treatment in patients with advanced solid state tumors.
Monday, June 01, 2015
AstraZeneca to Invest in New Biologics Manufacturing Facility
New facility in Södertälje, Sweden, to support accelerating biologics portfolio.
Thursday, May 21, 2015
AstraZeneca and Montreal Heart Institute Partner
AstraZeneca and Montreal Heart Institute to screen 80,000 samples for cardiovascular and diabetes genetic traits.
Thursday, May 14, 2015
AstraZeneca and Abbott Partner
AstraZeneca and Abbott to develop companion diagnostic tests for tralokinumab in severe asthma.
Thursday, May 14, 2015
AstraZeneca and Harvard Stem Cell Institute Collaborate
Collaboration will develop the use of stem cells for diabetes research.
Wednesday, March 25, 2015
AstraZeneca Forms CRISPR Collaborations
AstraZeneca announces collaborations to use CRISPR technology for genome editing across its drug discovery platform.
Thursday, January 29, 2015
AstraZeneca To Expand Its Frederick Biologics Manufacturing Center
$200+ million investment to support company’s maturing biologics pipeline.
Tuesday, November 25, 2014
Scientific News
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
Nanomedicine Aims to Improve HIV Drug Therapies
New research aims to improve the administration and availability of drug therapies to HIV patients using nanotechnology.
Tumor Markers Reveal Lethality Of Bladder Cancers
Researchers found that detection of certain tumor cells in early stage cancers helps identify high-risk cancers.
Gene Editing Corrects Sickle Cell Mutation
Researchers demonstrate a potential pathway to developing gene-editing treatments for sickle cell disease.
Driving Mosquito Evolution to Fight Malaria
Researchers propose insect repellent in conjunction with insecticides to extend current insecticide lifetime.
Lab-on-a-Chip to Help Detect Cancer
In this podcast, we speak to Gustavo Stolovitsky to learn about his career and the work he is doing at IBM Research.
ALS Study Reveals Role of RNA-Binding Proteins
The findings are a significant step forward in validating RNA-based therapy as a treatment for ALS.
Observing Direct Inheritance of Gene-Silencing RNA
Research has allowed for the observation of double-stranded RNA molecule being passed from parent to offspring in roundworms.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos